# Genentech Receives Exclusive Worldwide License from Astex for Breast Cancer Drug Discovery Program

> partnership · REPORTED · 2026-07-06

Astex Pharmaceuticals, an Otsuka subsidiary using fragment-based drug discovery, granted Genentech an exclusive worldwide license to compounds from an existing breast cancer drug discovery program targeting a cell-cycle-dependent regulator. The deal signals continued pipeline investment and modality expansion in breast oncology.

About Astex Pharmaceuticals / Genentech: Astex Pharmaceuticals is a clinical-stage oncology drug discovery company and Otsuka subsidiary specializing in fragment-based and structure-guided drug design, with a pipeline spanning breast cancer and other oncology indications.

- Company: Astex Pharmaceuticals / Genentech
- Sector: oncology
- Primary source: https://www.lqventures.com/womens-health-today-july-8-2026-lucidquest/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.